Lonza Houston, Inc. a provider of viral gene and cell therapy manufacturing, and Selecta Biosciences, a clinical-stage biopharma focused on developing biologic therapies for rare and serious diseases that avoid unwanted immunogenicity, have entered into a manufacturing agreement. Lonza will produce an Anc80-AAV-based gene therapy product for Selecta’s proprietary program for the treatment of methylmalonic acidemia (MMA), a rare inborn error of metabolism, and may in the future produce other Anc8...